Pericyazine

As a clinically derived variety of thiazide diuretics, cyclothiazide exerts the effects of sodium excretion and diuresis as well as reduction of peripheral vascular resistance by inhibiting the sodium-chloride cotransporter at the proximal end of the distal convoluted tubule and reducing the reabsorption of electrolytes and water. It is mainly used clinically for the antihypertensive treatment of essential hypertension, and can also assist in improving edema symptoms caused by diseases such as heart failure and nephrotic syndrome. Its applicable population covers patients with mild to moderate hypertension and edema patients intolerant to other diuretics, and it is one of the alternative drugs for diuretic-based antihypertensive regimens.

At present, the overall global market size of cyclothiazide is small, and there is no publicly verifiable statistical data related to market growth and competitive landscape.

The original research enterprise of cyclothiazide is Novartis, with the original trade name Diamox, and its core compound patent expired in 1960; the main dosage form of the original research product is oral tablet, with specifications including 250mg and 500mg. At present, this variety is not included in the *Catalogue of Reference Preparations for Chemical Drugs* issued by China NMPA, and the FDA Reference Preparation Catalogue has not yet included the relevant information of this variety. There is no registered DMF filing number for cyclothiazide active pharmaceutical ingredient in China, nor is there any approved and marketed cyclothiazide preparation product. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for cyclothiazide, most of which are available from stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the needs of impurity reference in the process of API R&D, quality research and production.